pING-HER3 Vaccine for Cancer - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out how an experimental vaccine (pING-hHER3FL) works in your body and against your cancer.

What is the Condition Being Studied?

Cancer

Who Can Participate in the Study?

People who:
- Have the one of the following cancers:
--Breast
--Colon
--Lung
--Prostate
--Ovarian
--Cervical
--Endometrial
--Gastric (stomach)
--Pancreatic
--Bladder
--Head and neck
--Liver
--Esophageal
- Have been treated with surgery and/or chemotherapy and radiation
- Have a protein called HER3 in the cancer cells

Age Group
Adults

What is Involved?

If you choose to do this study, you will:

- Get the study vaccine three times over 8 weeks
- Have occasional blood draws for 5 years
- Have a biopsy to collect tumor tissue, if necessary

Study Details

Full Title
ASSESSING THE IMMUNOGENICITY OF pING-hHER3FL VACCINE IN PATIENTS WITH RESECTED MALIGNANCIES
Principal Investigator
Protocol Number
IRB: PRO00104093
NCT: NCT03832855
Phase
Phase I
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698